Lysosomal diseases are rare, heterogeneous conditions affecting individuals over a dispersed geographic area. In order to facilitate research serving this unique population the Administrative Unit of the Lysosomal Disease Network will serve several important functions. Composed of five "Cores:" Administrative, Biostatistical, Neurobehaviroal, Neuroimaging, and Pharmacotherapy;the Units responsibilities are varied. The Administrative Unit will facilitate any communicationincluding go-to-meeting style web conferencesacross the Network. Members will assist all project PIs with regulatory and administrative responsibilities, including acting as liaison between PI and the DMCC. A newsletter will also be developed by members of this unit to highlight research and other accomplishments across Consortia. The Biostatistical Core has helped each PI with a proposed project in the development of the statistical needs for their work. With rare disease populations accurate statistical measurements are crucial and this core has the required expertise. Since almost all lysosomal conditions have component central nervous system disease the neuroimaging and neurobehavior cores provide essential consultation for all projects. In the first five years of this consortium, both cores made seminal discoveries regarding brain structure and function in lysosomal disease. New to the consortium this year is the Pharmacotherapy Core. Experts in the field of therapeutic development will be available to all members of the Network. Currently, all studies with treatment or other therapeutic regimens have consulted with the Core. All members of the Administrative Unit will assist the Training Unit in the implementation of new projects nad the mentoring of trainees.

Public Health Relevance

The Administrative Unit of the Lysosomal Disease Network will facilitate any and all core functions for all members of the Network. The Unit provides administrative, statistical, therapeutic, behavioral, and neurologic support. All members of the Unit will work with other project team members to successfully implement the goals of their individual projects

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
2U54NS065768-06
Application #
8918189
Study Section
Special Emphasis Panel (ZTR1-CI-8 (01))
Program Officer
Morris, Jill A
Project Start
Project End
Budget Start
2014-09-30
Budget End
2015-07-31
Support Year
6
Fiscal Year
2014
Total Cost
$314,158
Indirect Cost
$107,475
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Schneider, Joseph; Burmeister, Lynn A; Rudser, Kyle et al. (2016) Hypothyroidism in late-onset Pompe disease. Mol Genet Metab Rep 8:24-7
Polgreen, Lynda E; Vehe, Richard K; Rudser, Kyle et al. (2016) Elevated TNF-α is associated with pain and physical disability in mucopolysaccharidosis types I, II, and VI. Mol Genet Metab 117:427-30
Shapiro, Elsa G; Rudser, Kyle; Ahmed, Alia et al. (2016) A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II. Mol Genet Metab Rep 7:32-9
Dyke, J P; Sondhi, D; Voss, H U et al. (2016) Brain Region-Specific Degeneration with Disease Progression in Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease). AJNR Am J Neuroradiol 37:1160-9
Najafian, Behzad; Tøndel, Camilla; Svarstad, Einar et al. (2016) One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease. PLoS One 11:e0152812
Shapiro, E; King, K; Ahmed, A et al. (2016) The Neurobehavioral Phenotype in Mucopolysaccharidosis Type IIIB: an Exploratory Study. Mol Genet Metab Rep 6:41-47
Rappaport, Jeff; Manthe, Rachel L; Solomon, Melani et al. (2016) A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders. Mol Pharm 13:357-68
Ahmed, Alia; Shapiro, Elsa; Rudser, Kyle et al. (2016) Association of somatic burden of disease with age and neuropsychological measures in attenuated mucopolysaccharidosis types I, II and VI. Mol Genet Metab Rep 7:27-31
Karimian, Zahra; Whitley, Chester B; Rudser, Kyle D et al. (2016) Delayed Infusion Reactions to Enzyme Replacement Therapies. JIMD Rep :
Kazi, Zoheb B; Prater, Sean N; Kobori, Joyce A et al. (2016) Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses. JCI Insight 1:

Showing the most recent 10 out of 84 publications